The PennZone

PITTSBURGH--(BUSINESS WIRE)--Lipella Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on improving cancer survivorship, today announced it has begun recruiting patients in the company's phase 2a clinical trial to study the dose-dependent, safety and efficacy of LP-10 (liposomal tacrolimus) for the treatment of hemorrhagic cystitis.

"We are encouraged to be able to provide LP-10 to qualified patients," commented Jonathan Kaufman, Lipella's Chief Executive Officer. "Two clinical sites have started patient screening and recruitment, and we look forward to opening additional sites in the near future."

About Hemorrhagic Cystitis
Radiation used to treat prostate, colon, uterine, cervical and other pelvic cancers can cause chronic, painful urinary inflammation and blood loss called hemorrhagic cystitis. Certain chemotherapies (such as cyclophosphamide) can also cause this painful form of urinary bleeding. The blood loss, associated with hemorrhagic cystitis can lead to surgery, and can be fatal. There are currently no adequate therapies available for the treatment of moderate to severe hemorrhagic cystitis patients.

More on The PennZone

• Community, Conservation & Waterwise Inspiration Bloom on June 6
• Industrial and systems engineers celebrate key leaders in the field at IISE Annual Conference
• Cosanostra Miami Rises as the Best Latin Nightclub in Miami in Under Two Years From its Opening
• CCHR Leader's 50-Year Fight for Psychiatric Drug Victims Gains National Momentum
• Endless Mountain Music Festival Celebrates 21st Season with America250-Inspired Lineup

About LP-10
LP-10 is a proprietary liposomal formulation of tacrolimus that is currently being evaluated as a treatment for moderate to severe hemorrhagic cystitis. Lipella Pharmaceuticals received FDA Orphan Designation for the use of tacrolimus for the treatment of hemorrhagic cystitis.

About Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc. is a clinical stage pharmaceutical company with a focus on capital efficient therapeutic development opportunities, including the proprietary repositioning of generics for rare, morbid diseases that currently have no adequate treatments. Additional information is available at http://www.lipella.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve risks and uncertainties that could cause Lipella' results and the timing of certain events to differ materially from those discussed in the forward-looking statements, including risks associated with clinical development, regulatory approvals, product commercialization, intellectual property claims and litigation and other risks. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors.

More on The PennZone

• Author Releases 7-Day Screen Time Reset for Families as Teachers Worldwide Report Children "Struggling to Grasp Basic Concepts"
• Men's Health Month Begins with Record Proclamations, AP News Coverage, & National Momentum for Men's Health
• Blueshirt Media Launches HIPAA-Compliant AI Call Answering for Addiction Treatment Centers
• AdvisorVault Adds Social Media Archiving to its Consolidated D3P Service
• UK Financial Ltd Audits Full Ethereum Architecture Verifies Corporate Wallets and 19-Token Ecosystem Ahead of CoinMarketCap Filing for Global Ranking

Caution: LP-10 is currently not approved for commercial use in any indication in the United States and is limited by U.S. Federal Law to investigational use only.

Key words: hemorrhagic cystitis; radiation cystitis; phase-2a clinical trial; cancer survivorship; 505(b)(2) regulatory pathway; urinary bleeding; painful bladder; liposomal; drug; therapeutic; pharmaceutical

---

Show All News | Disclaimer | Report Violation